article thumbnail

Kellogg’s is going to war over Mexico’s nutrition label rules. A similar fight is coming to the U.S.

STAT

A 2019 policy requires companies that make unhealthy foods to include warning labels on the front of any boxes they sell in Mexico to educate consumers about things like excess sugar and fat. MEXICO CITY — Kellogg’s is waging a war here over Tigre Toño and Sam el Tucán.

article thumbnail

FDA-Approved Labeling: Is Enough Enough?

The FDA Law Blog

Livornese — I saw the sign…and the answer is no—FDA-approved labeling apparently is not enough under state failure-to-warn laws, according to certain courts. A recent state law failure-to-warn case in the SDNY makes that very point.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lilly bags label extension for RET drug Retevmo in US

pharmaphorum

The full approval also extends the Retevmo label to include patients with locally advanced as well as metastatic disease. Lilly acquired Retevmo as part of its $8 billion takeover of Loxo Oncology in 2019. The post Lilly bags label extension for RET drug Retevmo in US appeared first on.

article thumbnail

STAT+: Chick-fil-A drops a ‘No Antibiotic Ever’ pledge on chicken over supply issues

STAT

a decade after the chain announced it would implement a “No Antibiotics Ever” policy by 2019. Notably, Tyson Foods, which is one of the biggest poultry suppliers, a few months ago removed the “No Antibiotics Ever” label from its chickens after reportedly encountering higher costs.

Labelling 132
article thumbnail

Amgen builds Otezla’s psoriasis label as rival BMS looms large

pharmaphorum

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb’s much-touted rival deucravacitinib, which could make its debut next year. The post Amgen builds Otezla’s psoriasis label as rival BMS looms large appeared first on.

article thumbnail

Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement

Fierce Pharma

After a dispute over milestone payments derailed a 2019 heart med collaboration, Daiichi Sankyo and Esperion Therapeutics have mended fences with a $125 million settlement. |

article thumbnail

Harmony’s sleep disorder drug Wakix gets US label extension

pharmaphorum

Wakix (pitolisant) was first approved in August 2019 for treatment of excessive sleepiness in adults with narcolepsy. The company added another alternative, Xywav (calcium, magnesium, potassium, and sodium oxybates) earlier this year although these drugs lack the cataplexy use on their label.